Loading clinical trials...

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor | Clinical Trials | Clareo Health

TERMINATEDPhase 3

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466•GlaxoSmithKline

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Obstetric Labour, Premature

Interventions

Retosiban IV infusion

Placebo IV infusion

Locations

50

United States

Locations (50)

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Mobile, Alabama, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Colton, California, United States

GSK Investigational Site

Orange, California, United States

GSK Investigational Site

Washington D.C., District of Columbia, United States

Key Dates

Start Date

February 29, 2016

Primary Completion Date

July 24, 2017

Completion Date

July 24, 2017

Last Updated

July 28, 2020

Related Studies

COMPLETEDPhase 3

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

NCT02292784

Obstetric Labour, Premature

COMPLETEDPhase 1

Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women

NCT02377414

Obstetric Labour, Premature

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators

PPD Development, LP

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 28, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions